Tapespeed testers

OTS514 is a highly potent TOPK inhibitor with an IC 50 of 2.6 nM. OTS514 strongly suppresses the growth of TOPK-positive cancer cells OTS514 induces cell cycle arrest and apoptosis .In VitroOTS514 (1.5625-100 nM) induces cell cycle arrest and

OTS514 is a highly potent TOPK inhibitor with an IC 50 of 2.6 nM. OTS514 strongly suppresses the growth of TOPK-positive cancer cells OTS514 induces cell cycle arrest and apoptosis .In VitroOTS514 (1.5625-100 nM) induces cell cycle arrest and

OTS514 is a highly potent TOPK inhibitor with an IC 50 of 2.6 nM. OTS514 strongly suppresses the growth of TOPK-positive cancer cells OTS514 induces cell cycle arrest and apoptosis .In VitroOTS514 (1.5625-100 nM) induces cell cycle arrest and

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1

AD57 is an orally active multikinase inhibitor, inhibits RET , BRAF , S6K and Src , with greatly reduces mTOR activityIn VitroAD57 (0.2 nM) significantly inhibits the ptc &gt: dRet MEN2B lethality in the larva of Drosophila. AD57 (0.1 nM) enhances

AD57 is an orally active multikinase inhibitor, inhibits RET , BRAF , S6K and Src , with greatly reduces mTOR activityIn VitroAD57 (0.2 nM) significantly inhibits the ptc &gt: dRet MEN2B lethality in the larva of Drosophila. AD57 (0.1 nM) enhances

AD57 is an orally active multikinase inhibitor, inhibits RET , BRAF , S6K and Src , with greatly reduces mTOR activityIn VitroAD57 (0.2 nM) significantly inhibits the ptc &gt: dRet MEN2B lethality in the larva of Drosophila. AD57 (0.1 nM) enhances

AD57 is an orally active multikinase inhibitor, inhibits RET , BRAF , S6K and Src , with greatly reduces mTOR activityIn VitroAD57 (0.2 nM) significantly inhibits the ptc &gt: dRet MEN2B lethality in the larva of Drosophila. AD57 (0.1 nM) enhances